What is he best known for?
The fields of study he is best known for:
Mark A. Wainberg mainly investigates Virology, Reverse transcriptase, Virus, Molecular biology and Drug resistance.
His research in Virology is mostly concerned with Viral replication.
His work carried out in the field of Reverse transcriptase brings together such families of science as Nucleotidyltransferase, Mutant, Zidovudine and Primer.
His study focuses on the intersection of Virus and fields such as Amino acid with connections in the field of Capsid.
The various areas that Mark A. Wainberg examines in his Molecular biology study include Cell culture, Transfection, RNA, DNA synthesis and Transcription.
His Drug resistance research includes themes of Acquired immunodeficiency syndrome, Lentivirus, Viral load, Immunology and Genotype.
His most cited work include:
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients: The INCAS Trial (687 citations)
- High Rates of Forward Transmission Events after Acute/Early HIV-1 Infection (550 citations)
- Public health implications of antiretroviral therapy and HIV drug resistance (465 citations)
What are the main themes of his work throughout his whole career to date?
Virology, Reverse transcriptase, Virus, Molecular biology and Drug resistance are his primary areas of study.
His research on Virology focuses in particular on Viral replication.
His study explores the link between Reverse transcriptase and topics such as Nevirapine that cross with problems in Efavirenz.
His Virus research includes elements of Cell culture and In vitro.
The concepts of his Molecular biology study are interwoven with issues in RNA, Mutant, DNA, Enzyme and Primer binding site.
His study in Drug resistance is interdisciplinary in nature, drawing from both Transmission, Viral load and Pharmacology, Drug.
He most often published in these fields:
- Virology (91.54%)
- Reverse transcriptase (44.10%)
- Virus (41.87%)
What were the highlights of his more recent work (between 2012-2021)?
- Virology (91.54%)
- Dolutegravir (15.81%)
- Integrase (18.71%)
In recent papers he was focusing on the following fields of study:
His main research concerns Virology, Dolutegravir, Integrase, Drug resistance and Raltegravir.
His Virology research integrates issues from Mutation, Genetics and Reverse transcriptase.
His research in Reverse transcriptase intersects with topics in Nevirapine, Molecular biology, Lamivudine and Rilpivirine.
His Dolutegravir study deals with Elvitegravir intersecting with Cabotegravir.
The Integrase study combines topics in areas such as Integrase inhibitor and Resistance mutation.
Within one scientific family, he focuses on topics pertaining to Viral load under Raltegravir, and may sometimes address concerns connected to Acquired immunodeficiency syndrome.
Between 2012 and 2021, his most popular works were:
- Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study (200 citations)
- CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. (146 citations)
- CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. (146 citations)
In his most recent research, the most cited papers focused on:
Mark A. Wainberg focuses on Virology, Dolutegravir, Integrase, Drug resistance and Raltegravir.
His Virology research is multidisciplinary, relying on both Mutation, Genetics and Resistance mutation.
His Dolutegravir research incorporates themes from Integrase inhibitor, HIV drug resistance, Elvitegravir and Pharmacology.
His Integrase study incorporates themes from Reverse transcriptase and Binding site.
Mark A. Wainberg has researched Drug resistance in several fields, including Regimen and Drug.
He combines subjects such as Molecular biology, Antibody and In vivo with his study of Viral replication.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
